Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi/Aventis Merger Will Not Affect Exubera, Actonel Agreements – Sanofi

Executive Summary

Sanofi-Synthelabo does not expect merging with Aventis would negatively affect Aventis' co-promotion agreements for Actonel and Exubera, CEO Jean-Francois Dehecq said during a March 11 investor call

You may also be interested in...



Aventis Cites Plavix Patent Litigation In Countering Sanofi’s Takeover Bid

Apotex and Dr. Reddy's have raised a "substantial challenge" to the validity of Sanofi-Synthelabo's compound patent for Plavix, Aventis says in a Securities & Exchange Commission filing

Aventis Cites Plavix Patent Litigation In Countering Sanofi’s Takeover Bid

Apotex and Dr. Reddy's have raised a "substantial challenge" to the validity of Sanofi-Synthelabo's compound patent for Plavix, Aventis says in a Securities & Exchange Commission filing

Aventis Would Provide Critical Mass For Sanofi’s Mid-Term R&D – Sanofi CEO

Sanofi-Synthelabo's proposed merger with Aventis would provide the critical mass necessary to support the development of Sanofi's early to mid-stage pipeline, CEO Jean-Francois Dehecq said

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel